These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 35262108)

  • 1. Metallodrugs in cancer nanomedicine.
    Peña Q; Wang A; Zaremba O; Shi Y; Scheeren HW; Metselaar JM; Kiessling F; Pallares RM; Wuttke S; Lammers T
    Chem Soc Rev; 2022 Apr; 51(7):2544-2582. PubMed ID: 35262108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects.
    Sarpong-Kumankomah S; Gailer J
    Curr Top Med Chem; 2021; 21(1):48-58. PubMed ID: 32600232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview.
    El Kazzouli S; El Brahmi N; Mignani S; Bousmina M; Zablocka M; Majoral JP
    Curr Med Chem; 2012; 19(29):4995-5010. PubMed ID: 22963626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines in the treatment of colon cancer: a focus on metallodrugs.
    Farinha P; Pinho JO; Matias M; Gaspar MM
    Drug Deliv Transl Res; 2022 Jan; 12(1):49-66. PubMed ID: 33616870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-atom simulations to studying metallodrugs/target interactions.
    Janoš P; Spinello A; Magistrato A
    Curr Opin Chem Biol; 2021 Apr; 61():1-8. PubMed ID: 32781390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
    Liu W; Gust R
    Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimuli-Responsive Therapeutic Metallodrugs.
    Wang X; Wang X; Jin S; Muhammad N; Guo Z
    Chem Rev; 2019 Jan; 119(2):1138-1192. PubMed ID: 30299085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR spectroscopy to study the fate of metallodrugs in cells.
    Arnesano F
    Curr Opin Chem Biol; 2021 Apr; 61():214-226. PubMed ID: 33882391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supramolecular coordination complexes as diagnostic and therapeutic agents.
    Yu G; Jiang M; Huang F; Chen X
    Curr Opin Chem Biol; 2021 Apr; 61():19-31. PubMed ID: 33147551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostics Through the Synergistic Cooperation of Heterometallic Complexes.
    Redrado M; Fernández-Moreira V; Gimeno MC
    ChemMedChem; 2021 Mar; 16(6):932-941. PubMed ID: 33305458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metallodrugs: an approach against invasion and metastasis in cancer treatment.
    González-Ballesteros MM; Mejía C; Ruiz-Azuara L
    FEBS Open Bio; 2022 May; 12(5):880-899. PubMed ID: 35170871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies.
    Adhikari S; Nath P; Das A; Datta A; Baildya N; Duttaroy AK; Pathak S
    Biomed Pharmacother; 2024 Feb; 171():116211. PubMed ID: 38290253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are smart delivery systems the solution to overcome the lack of selectivity of current metallodrugs in cancer therapy?
    Franco Machado J; Morais TS
    Dalton Trans; 2022 Feb; 51(7):2593-2609. PubMed ID: 35106525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: Mechanism-driven new therapy development.
    Wang H; Zhou Y; Xu X; Li H; Sun H
    Curr Opin Chem Biol; 2020 Apr; 55():171-179. PubMed ID: 32200302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal/N-heterocyclic carbene complexes: opportunities for the development of anticancer metallodrugs.
    Cisnetti F; Gautier A
    Angew Chem Int Ed Engl; 2013 Nov; 52(46):11976-8. PubMed ID: 24115500
    [No Abstract]   [Full Text] [Related]  

  • 20. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.
    Liu J; Lai H; Xiong Z; Chen B; Chen T
    Chem Commun (Camb); 2019 Aug; 55(67):9904-9914. PubMed ID: 31360938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.